TY - JOUR
T1 - Cabozantinib in the treatment of advanced renal cell carcinoma
T2 - Design, development, and potential place in the therapy
AU - Grassi, Paolo
AU - Verzoni, Elena
AU - Ratta, Raffaele
AU - Mennitto, Alessia
AU - de Braud, Filippo
AU - Procopio, Giuseppe
PY - 2016/7/5
Y1 - 2016/7/5
N2 - The treatment of metastatic renal cell carcinoma (mRCC) has markedly improved over the last few years with the introduction of several targeted agents in clinical practice. Nevertheless, either primary or secondary resistance to inhibition of VEGF and mTOR pathways has limited the clinical benefit of these systemic treatments. Recently, a better understanding of the involvement of MET and its ligand HGF in many biological processes made this signaling pathway an attractive therapeutic target in oncology, particularly in mRCC. Herein, we review the development of cabozantinib, a recently approved inhibitor of multiple tyrosine kinase receptors, including MET, VEGFRs, and AXL, which has proven to increase progression-free survival and overall survival when compared to everolimus in mRCC patients who had progressed after VEGFR-targeted therapy. Finally, we discuss the potential role of cabozantinib within the current treatment landscape for mRCC.
AB - The treatment of metastatic renal cell carcinoma (mRCC) has markedly improved over the last few years with the introduction of several targeted agents in clinical practice. Nevertheless, either primary or secondary resistance to inhibition of VEGF and mTOR pathways has limited the clinical benefit of these systemic treatments. Recently, a better understanding of the involvement of MET and its ligand HGF in many biological processes made this signaling pathway an attractive therapeutic target in oncology, particularly in mRCC. Herein, we review the development of cabozantinib, a recently approved inhibitor of multiple tyrosine kinase receptors, including MET, VEGFRs, and AXL, which has proven to increase progression-free survival and overall survival when compared to everolimus in mRCC patients who had progressed after VEGFR-targeted therapy. Finally, we discuss the potential role of cabozantinib within the current treatment landscape for mRCC.
KW - c-Met
KW - Cabozantinib
KW - Metastatic renal cell carcinoma
KW - Targeted therapy
KW - VEGF-inhibitor
KW - XL-184
UR - http://www.scopus.com/inward/record.url?scp=84978970987&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978970987&partnerID=8YFLogxK
U2 - 10.2147/DDDT.S104225
DO - 10.2147/DDDT.S104225
M3 - Review article
AN - SCOPUS:84978970987
VL - 10
SP - 2167
EP - 2172
JO - Drug Design, Development and Therapy
JF - Drug Design, Development and Therapy
SN - 1177-8881
ER -